The U.K. Office of Fair Trading is investigating allegations that GlaxoSmithKline has been paying competitors to delay market entry of their own versions of the GSK antidepressant Seroxat. If the watchdog agency decides that GSK was in violation, the drugmaker could be liable for fines of up to 30% of revenue during the period that the payments were made. "GSK supports fair competition and we very strongly believe that we acted within the law," the company said in a statement, vowing to cooperate fully in the investigation.

Related Summaries